NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

166.60B

Vuru Grade

69.64/100

Current Price

$70.13
-0.01 (-0.01%)

Growth Price

$56.17
Overvalued by 19.90%

Stability Price

$14.61
Overvalued by 79.17%

Company Metrics

  • P/E 24.73
  • P/S 3.36
  • P/B 2.22
  • EPS 2.84
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.85%
  • Avg. Vol. 3.50M
  • Shares 2.38B
  • Market Cap. 166.60B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Novartis AG (ADR) (NVS) Q3 Earnings: What Leerink Expects
Smаrt Stоck Nеws - Oct 20, 2016
Leerink's 2016 EPS estimate for Novartis stands at $4.8 on revenue of $50.5 billion, compared to consensus of $4.7 and $49 billion, respectively.
Shares of Novartis AG (NYSE:NVS) Sees Large Inflow of Net Money Flow
Highland Mirror - 18 hours ago
Novartis AG (ADR) Last issued its quarterly earnings results on Oct 25, 2016. The company reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.06.
Earnings in Focus: Novartis (NVS) - News Oracle
Analyst Views on Price Target: Novartis AG (ADR) (NYSE:NVS)
Post Registrar - Jan 18, 2017
Novartis AG (ADR) (NYSE:NVS) plunged -0.57% during previous trade, a total of 7.41M shares exchanged hands compared with its average trading volume of 3.15M shares whereas its relative volume is 2.25.
Stocks to Track Novartis AG (ADR) (NYSE:NVS), Lifelock Inc (NYSE:LOCK) - Wall Street 24
Broker's Roundup on Rating and Recommendations: Novartis AG (ADR) (NYSE:NVS)
Post Registrar - Jan 12, 2017
Novartis AG (ADR) (NYSE:NVS) fell -1.88% during previous trade. Credit Suisse issued rating on the stock of Novartis AG (ADR) (NYSE:NVS) in a research note issued to investors on Jan-11-16, the stock received “Downgrade” rating from Outperform to ...
What Analysts say about Novartis AG (ADR) (NYSE:NVS) - Review Fortune
Here's What The Novartis AG (ADR) (NYSE:NVS) Deal Means For Conatus ...
Market Exclusive - Dec 20, 2016
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) just announced that it has inked a deal with pharma giant Novartis AG (ADR) (NYSE:NVS); a deal that will see the latter team up with the microcap on the development of a drug called Emricasan. It's a NASH ...
Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus ... - Insider Monkey (blog)
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Updates On Collaboration Contract ... - Journal Transcript
Ionis Pharmaceuticals Inc (IONS), Akcea Strike Favorable Deal with Novartis AG ...
Smarter Analyst - Jan 6, 2017
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares were initially up 6% this morning after the biotech firm and its wholly-owned subsidiary Akcea Therapeutics signed an exclusive cardiovascular disease treatment collaborative agreement with Novartis AG ...
Analyst Viewpoints on Price Reaction History: Novartis AG (ADR) (NYSE:NVS)
Post Registrar - Dec 28, 2016
Novartis AG (ADR) (NYSE:NVS) soared 0.24% during previous trade, a total of 1.86M shares exchanged hands compared with its average trading volume of 3.16M shares whereas its relative volume is 0.60.
Zacks Investment Research upgraded Novartis AG (ADR) (NYSE:NVS) to Hold in a ... - Breaking Finance News
Analyst Review Alert on Price Target: Novartis AG (ADR) (NYSE:NVS)
Post Registrar - Dec 9, 2016
Novartis AG (ADR) (NYSE:NVS) plunged -1.50% during previous trade, a total of 5.42M shares exchanged hands compared with its average trading volume of 3.39M shares whereas its relative volume is 1.96.
European Influenza Market May Reach Close To $650 Million by 2021, Who Stands ... - Stock Market Daily (blog)
Novartis AG (ADR) (NVS) is Downgraded by Credit Suisse to Neutral
Highland Mirror - Jan 11, 2017
On the company's financial health, Novartis AG (ADR) reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Oct 25, 2016.
Novartis AG (ADR) (NYSE:NVS) target price raised to $71.91, issued a report ... - Breaking Finance News
Novartis AG (NVS) May Fancy AstraZeneca plc (AZN) for Takoever: Reports
Smаrt Stоck Nеws - Nov 12, 2016
The American depository receipts of AstraZeneca plc (ADR) (NYSE:AZN) traded up over 1% on the New York exchange Friday, after a report suggested that the company may attract a takeover interest from Novartis AG (ADR) (NYSE:NVS). Novartis' ADRs ...